Literature DB >> 22875644

Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?

Ninos Ayez1, Wijnand J Alberda, Jacobus W A Burger, Alexander M M Eggermont, Joost J M E Nuyttens, Roy S Dwarkasing, François E J A Willemssen, Cornelis Verhoef.   

Abstract

BACKGROUND: There is no evidence regarding restaging of patients with locally advanced rectal cancer after a long course of neoadjuvant radiotherapy with or without chemotherapy. This study evaluated the value of restaging with chest and abdominal computed tomographic (CT) scan after radiotherapy.
METHODS: Between January 2000 and December 2010, all newly diagnosed patients in our tertiary referral hospital, who underwent a long course of radiotherapy for locally advanced rectal cancer, were analyzed. Patients were only included if they had chest and abdominal imaging before and after radiotherapy treatment.
RESULTS: A total of 153 patients who met the inclusion criteria and were treated with curative intent were included. A change in treatment strategy due to new findings on the CT scan after radiotherapy was observed in 18 (12%) of 153 patients. Twelve patients (8%) were spared rectal surgery due to progressive metastatic disease.
CONCLUSIONS: Restaging with a chest and abdominal CT scan after radiotherapy for locally advanced rectal cancer is advisable because additional findings may alter the treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875644     DOI: 10.1245/s10434-012-2537-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system.

Authors:  Antonio Manenti; Luca Roncati; Massimiliano Salati; Emilio Simonini; Maurizio Zizzo; Alberto Farinetti
Journal:  J Gastrointest Oncol       Date:  2017-02

2.  Restaging Abdominopelvic Computed Tomography Before Surgery After Preoperative Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.

Authors:  Hyo Jung Park; Jong Keon Jang; Seong Ho Park; In Ja Park; Jong Hoon Kim; Seunghee Baek; Yong Sang Hong
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

3.  Restaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection?

Authors:  Nitin Singhal; Karthik Vallam; Reena Engineer; Vikas Ostwal; Supreeta Arya; Avanish Saklani
Journal:  J Gastrointest Oncol       Date:  2016-06

4.  Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).

Authors:  Zhengyang Yang; Xiao Zhang; Jie Zhang; Jiale Gao; Zhigang Bai; Wei Deng; Guangyong Chen; Yongbo An; Yishan Liu; Qi Wei; Jiagang Han; Ang Li; Gang Liu; Yi Sun; Dalu Kong; Hongwei Yao; Zhongtao Zhang
Journal:  BMC Cancer       Date:  2022-04-27       Impact factor: 4.638

5.  The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.

Authors:  Guo-Chen Liu; Xu Zhang; E Xie; Xin An; Pei-Qiang Cai; Ying Zhu; Jing-Hua Tang; Ling-Heng Kong; Jun-Zhong Lin; Zhi-Zhong Pan; Pei-Rong Ding
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.